Vir Bio (VIR) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

VIR Stock Forecast


Vir Bio (VIR) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $15.00, with a high of $15.00 and a low of $15.00. This represents a 101.34% increase from the last price of $7.45.

$7 $8 $9 $10 $11 $12 $13 $14 $15 High: $15 Avg: $15 Low: $15 Last Closed Price: $7.45

VIR Stock Rating


Vir Bio stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (81.82%), 2 Hold (18.18%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 2 9 Strong Sell Sell Hold Buy Strong Buy

VIR Price Target Upside V Benchmarks


TypeNameUpside
StockVir Bio101.34%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends


1M3M12M
# Anlaysts112
Avg Price Target$15.00$15.00$13.50
Last Closing Price$7.45$7.45$7.45
Upside/Downside101.34%101.34%81.21%
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2646---10
Dec, 2546---10
Nov, 2555---10
Oct, 2555---10
Sep, 2554---9
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 30, 2025Patrick TrucchioH.C. Wainwright$15.00$5.98150.84%101.34%
Jul 11, 2025Sean McCutcheonRaymond James$12.00$5.65112.39%61.07%
Jan 09, 2025Michael UlzMorgan Stanley$20.00$7.89153.49%168.46%
Aug 02, 2024Gena WangBarclays$28.00$9.73187.77%275.84%
Jun 05, 2024Michael UlzMorgan Stanley$15.00$12.6618.48%101.34%
May 21, 2024Gena WangBarclays$27.00$9.69178.64%262.42%
Feb 21, 2023Paul ChoiGoldman Sachs$28.38$25.7410.26%280.94%
May 06, 2022Joseph StringerNeedham$35.00$21.8760.04%369.80%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
Jan 13, 2026BenchmarkBuyBuyhold
Dec 30, 2025H.C. WainwrightBuyBuyhold
Dec 08, 2025NeedhamBuyBuyhold
Sep 03, 2025Evercore ISIOutperforminitialise
Jul 11, 2025Raymond JamesOutperforminitialise
Feb 28, 2025BarclaysOverweightOverweighthold
Jan 09, 2025Morgan StanleyEqual-WeightOverweightupgrade
Aug 02, 2024NeedhamBuyBuyhold
Aug 02, 2024BarclaysOverweightOverweighthold
Jun 05, 2024Morgan StanleyEqual-WeightEqual-Weighthold

Financial Forecast


EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.07$3.89$-4.59$-3.83----
Avg Forecast$2.70$4.31$-4.66$-3.88$-3.54$-3.44$-2.78$-1.92
High Forecast$5.09$7.98$-3.62$-3.66$-2.59$-2.96$-1.85$0.07
Low Forecast$1.42$1.79$-5.42$-3.98$-4.51$-4.01$-3.32$-3.90
Surprise %50.74%-9.74%-1.50%-1.29%----

Revenue Forecast

$0 $600M $1B $2B $2B $3B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.09B$1.58B$86.18M$74.20M----
Avg Forecast$905.58M$1.71B$79.68M$68.66M$30.36M$32.45M$84.42M$289.68M
High Forecast$1.52B$2.83B$105.05M$95.87M$54.58M$33.17M$151.76M$520.71M
Low Forecast$573.97M$942.29M$68.07M$58.31M$6.20M$31.74M$17.23M$59.13M
Surprise %20.04%-7.73%8.16%8.08%----

Net Income Forecast

$-2B $-1B $-500M $0 $500M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$528.58M$515.84M$-615.06M$-521.96M----
Avg Forecast$341.01M$396.47M$-615.06M$-533.34M$-535.68M$-467.09M$-346.71M$-256.89M
High Forecast$669.82M$719.43M$-114.04M$-491.49M$-347.75M$-396.77M$-247.65M$8.90M
Low Forecast$12.20M$73.51M$-1.12B$-533.99M$-604.56M$-537.42M$-445.77M$-523.24M
Surprise %55.00%30.11%--2.13%----

VIR Forecast FAQ


Is Vir Bio stock a buy?

Vir Bio stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Vir Bio is a favorable investment for most analysts.

What is Vir Bio's price target?

Vir Bio's price target, set by 11 Wall Street analysts, averages $15 over the next 12 months. The price target range spans from $15 at the low end to $15 at the high end, suggesting a potential 101.34% change from the previous closing price of $7.45.

How does Vir Bio stock forecast compare to its benchmarks?

Vir Bio's stock forecast shows a 101.34% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Vir Bio over the past three months?

  • January 2026: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Vir Bio’s EPS forecast?

Vir Bio's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.54, marking a -7.57% decrease from the reported $-3.83 in 2024. Estimates for the following years are $-3.44 in 2026, $-2.78 in 2027, and $-1.92 in 2028.

What is Vir Bio’s revenue forecast?

Vir Bio's average annual revenue forecast for its fiscal year ending in December 2025 is $30.36M, reflecting a -59.08% decrease from the reported $74.2M in 2024. The forecast for 2026 is $32.45M, followed by $84.42M for 2027, and $289.68M for 2028.

What is Vir Bio’s net income forecast?

Vir Bio's net income forecast for the fiscal year ending in December 2025 stands at $-536M, representing an 2.63% increase from the reported $-522M in 2024. Projections indicate $-467M in 2026, $-347M in 2027, and $-257M in 2028.